Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia

International Clinical Psychopharmacology

Volumn 32, Issue 3, 2017, Pages 169-173

  Nakata, Yusuke ^a   Kanahara, Nobuhisa ^b   Kimura, Hiroshi ^a,c   Watanabe, Hiroyuki ^b   Iyo, Masaomi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

antipsychotic; dopamine receptor; dopamine supersensitivity; treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MALE; MIDDLE AGED; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; YOUNG ADULT; CASE REPORT; CENTRAL NERVOUS SYSTEM SENSITIZATION; DRUG EFFECTS; DRUG RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM SENSITIZATION; CLOZAPINE; DOPAMINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85008698548     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000160     Document Type: Article

References (31)

1. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, et al. (2004). Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 161:1822-1828.
2. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998). Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155:751-760.
3. Chouinard G (1991). Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5:21-33.
4. Chouinard G, Jones BD (1980). Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137:16-21.
5. Chouinard G, Sultan S (1990). Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol Bull 26:337-341.
6. Chouinard G, Chouinard VA (2008). Atypical Antipsychotics. CATIE Study, druginduced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77:69-77.
7. Chouinard G, Jones BD, Annable L (1978). Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135:1409-1410.
8. Chouinard G, Annable L, Ross-Chouinard A (1986). Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull 22:891-896.
9. Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, et al. (1994). Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 18:1129-1141.
10. Conley RR, Tamminga CA, Kelly DL, Richardson CM (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. J Psychopharmacol 46:73-77.
11. Daskalakis ZJ, George TP (2009). Clozapine, GABAB, and the treatment of resistant schizophrenia. Transl Med 86:442-446.
12. Fakra E, Azorin JM (2012). Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 13:1923-1935.
13. Gardos G, Cole JO, Tarsy D (1978). Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 135:1321-1324.
14. Gill KM, Cook JM, Poe MM, Grace AA (2014). Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull 40:341-350.
15. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. (1997). Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321:105-111.
16. Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, et al. (2013). Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398-404.
17. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369.
18. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
19. Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura K, et al. (2014). A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 155:52-58.
20. Kirkpatrick B, Alphs L, Buchanan RW (1992). The concept of supersensitivity psychosis. J Nerv Ment Dis 180:265-270.
21. Khler U, Schrder H, Augusatin W, Sabel BA (1994). A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci Lett 170:99-102.
22. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744-1752.
23. Louza MR, Bassitt DP (2005). Maintenance treatment of severe tardive dyskinesia with clozapine. 5 years follow-up. J Clin Psychopharmacology 25:180-182.
24. Meltzer HY (1989). Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99 (Suppl):18S-27S.
25. Michel FJ, Trudeau LE (2000). Clozapine inhibits synaptic transmission at GABAnergic synapses established by ventral tegmental area neurons in culture. Neuropharmacology 39:1536-1543.
26. Moncrieff J (2006). Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersenstivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114:3-13.
27. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986.
28. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. (2000). Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180.
29. Sur C, Mallorga PJ, Wittman M, Jacobson MA, Pascarella D, Williams JB, et al. (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679.
30. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, et al. (2015). Dopamine supersensitivity psychosis as a pivotal factor in treatmentresistant schizophrenia. Psychiatr Res 227:278-282.
31. Wong AH, van Tol HH (2003). The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1091-1099.